What is the 13F Pro Quality Score for AMLX?

13F Pro ranks Amylyx Pharmaceuticals, Inc. (AMLX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View AMLX's current score at https://13fpro.ai/research/AMLX (free sign-up required for the full ranking).

Which hedge funds own the most AMLX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of AMLX include FMR, BlackRock,, PERCEPTIVE ADVISORS. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/AMLX as soon as new 13F filings post.

Where does 13F Pro source AMLX data?

All Amylyx Pharmaceuticals, Inc. fundamentals and ownership data come directly from SEC EDGAR. Amylyx Pharmaceuticals, Inc. files with the SEC under CIK 1658551. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is AMLX in?

Amylyx Pharmaceuticals, Inc. (AMLX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is AMLX research updated on 13F Pro?

AMLX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Amylyx Pharmaceuticals, Inc.(AMLX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1658551 AMLX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

AMLX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Amylyx Pharmaceuticals, Inc. (AMLX), a Healthcare sector company. AMLX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Amylyx Pharmaceuticals, Inc. reports net income of $-41.3M, free cash flow of $-36.9M. Top institutional holders of AMLX by reported 13-F value include FMR, BlackRock,, PERCEPTIVE ADVISORS, based on the most recent SEC filings. AMLX trades on the Nasdaq exchange and files with the SEC under CIK 1658551. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AMLX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Amylyx Pharmaceuticals, Inc. directly from SEC EDGAR. Amylyx Pharmaceuticals, Inc.'s 13F Pro composite quality score has ranged between 7 and 41 since 2024, currently 7.0 — a declining long-term trajectory across 8 quarterly and live scoring snapshots.

Net Income

Q1 2026

$-41.3M

Free Cash Flow

Q1 2026

$-36.9M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-100.0% YoY

$0.00FY 2025

FY22 $22.2MFY23 $380.8MFY24 $87.4MFY25 $0.00

Net Income

+52.0% YoY

$-144.7MFY 2025

FY22 $-198.4MFY23 $49.3MFY24 $-301.7MFY25 $-144.7M

Operating Income

+51.3% YoY

$-153.3MFY 2025

FY22 $-201.3MFY23 $38.8MFY24 $-314.7MFY25 $-153.3M

EPS (Diluted)

+65.5% YoY

$-1.53FY 2025

FY22 $-3.39FY23 $0.70FY24 $-4.43FY25 $-1.53

Total Assets

+71.8% YoY

$332.6MFY 2025

FY22 $391.5MFY23 $517.5MFY24 $193.6MFY25 $332.6M

Op. Cash Flow

+26.4% YoY

$-123.3MFY 2025

FY22 $-179.9MFY23 $11.9MFY24 $-167.6MFY25 $-123.3M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	$0.00 -100.0%	$87.4M -77.1%	$380.8M +1612.9%	$22.2M +7700.0%	$285.0K
Net Income	$-144.7M +52.0%	$-301.7M -712.4%	$49.3M +124.8%	$-198.4M -125.6%	$-87.9M
Operating Income	$-153.3M +51.3%	$-314.7M -911.1%	$38.8M +119.3%	$-201.3M -143.5%	$-82.7M
EPS (Diluted)	$-1.53 +65.5%	$-4.43 -732.9%	$0.70 +120.6%	$-3.39 +74.6%	$-13.35
Total Assets	$332.6M +71.8%	$193.6M -62.6%	$517.5M +32.2%	$391.5M +270.6%	$105.6M
Operating Cash Flow	$-123.3M +26.4%	$-167.6M -1506.6%	$11.9M +106.6%	$-179.9M -140.5%	$-74.8M

AI Insight: AMLX Financial Trends

Amylyx remains a pre-revenue burn story, though quarterly cash burn has roughly halved from Q2 2024 peaks while equity was bolstered mid-2025.

• Operating loss narrowed from -$76M in Q2 2024 to -$36M in Q4 2025, suggesting meaningful cost reduction over six quarters.

• Operating cash outflow improved from -$67M in Q2 2024 to -$28M in Q4 2025, a 58% reduction in quarterly cash burn.

• Revenue has registered $0M across every reported quarter from Q3 2024 through Q4 2025 — the company generates no product revenue.

• Equity surged from $168M in Q2 2025 to $332M in Q3 2025, likely reflecting a capital raise, before declining to $273M in Q1 2026.

⚠ Operating loss widened to -$44M in Q1 2026 from -$37M in Q4 2025 — first sequential deterioration in three quarters.

⚠ Equity eroding steadily from $332M in Q3 2025 to $273M in Q1 2026; runway depends entirely on future capital raises.

⚠ Zero revenue across all reported periods makes any pipeline catalyst or partnership announcement the sole valuation inflection point.

AI Insight: AMLX Ratio Trends

Return metrics remain deeply negative but show meaningful improvement from peak losses, with ROE narrowing from -148.2% in Q3 2024 to -43.2% by Q4 2025 before re-widening in Q1 2026.

• ROE improved sharply from -148.2% in Q3 2024 to -41.4% in Q3 2025, suggesting significant loss reduction over four quarters.

• ROE re-widened to -60.5% in Q1 2026 from -43.2% in Q4 2025, reversing the prior improvement trend.

• ROIC moved from -98.7% in Q4 2024 to -43.4% in Q3 2025, then deteriorated again to -64.1% in Q1 2026.

⚠ Q1 2026 re-widening in ROE (-60.5%) and ROIC (-64.1%) after two quarters of relative stabilization warrants close monitoring.

⚠ OpMargin, NPM, and D/E are entirely absent across all periods, leaving capital structure and profitability dynamics largely opaque.

Get alerted when AMLX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Amylyx Pharmaceuticals, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of AMLX

FMR LLC
$231.2M16,630,541 sh
BlackRock, Inc.
$122.7M8,828,836 sh
PERCEPTIVE ADVISORS LLC
$115.2M8,284,882 sh
TCG Crossover Management, LLC
$86.8M6,243,812 sh
Commodore Capital LP
$78.5M5,650,000 sh
JANUS HENDERSON GROUP PLC
$69.3M4,986,073 sh
Saturn V Capital Management LP
$60.5M4,349,885 sh
VANGUARD CAPITAL MANAGEMENT LLC
$57.6M4,141,575 sh
ADAGE CAPITAL PARTNERS GP, L.L.C.
$49.5M3,560,764 sh
First Light Asset Management, LLC
$44.3M3,190,645 sh

Fund	Value	Shares
FMR LLC	$231.2M	16,630,541
BlackRock, Inc.	$122.7M	8,828,836
PERCEPTIVE ADVISORS LLC	$115.2M	8,284,882
TCG Crossover Management, LLC	$86.8M	6,243,812
Commodore Capital LP	$78.5M	5,650,000
JANUS HENDERSON GROUP PLC	$69.3M	4,986,073
Saturn V Capital Management LP	$60.5M	4,349,885
VANGUARD CAPITAL MANAGEMENT LLC	$57.6M	4,141,575
ADAGE CAPITAL PARTNERS GP, L.L.C.	$49.5M	3,560,764
First Light Asset Management, LLC	$44.3M	3,190,645

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put AMLX on your watchlist

Track score changes the day Amylyx Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is AMLX a good stock to buy?

13F Pro's AI-powered analysis of Amylyx Pharmaceuticals, Inc. (AMLX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AMLX are available on the AMLX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own AMLX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AMLX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Amylyx Pharmaceuticals, Inc.'s investment landscape.